<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022722</url>
  </required_header>
  <id_info>
    <org_study_id>UC IRB Study #: 2013-0677</org_study_id>
    <secondary_id>Patty Brisben Foundation</secondary_id>
    <nct_id>NCT02022722</nct_id>
  </id_info>
  <brief_title>Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain</brief_title>
  <official_title>Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patty Brisben Foundation For Women's Sexual Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate which treatment option for pelvic floor pain allows
      for improved sexual function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic floor pain may be treated with trigger point injections with medications (steroids and
      local anesthetics) that are FDA approved for injection into muscles. The alternative is a
      noninvasive treatment option using pelvic rehabilitation which involves vaginal muscle
      massage. Both treatment options have been used and reported; however, rapidity of improvement
      and return to normal sexual function have not been assessed. This study assigns patients to
      either treatment option randomly and the sexual function is assessed based on standardized
      sexual function questionnaires as well as pain ratings.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in rating of pain from baseline until the end of the study according to the Iowa Pain Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Patients will be asked to rate their current pain prior to initiation of the treatment at the visits, at the start of the study and after the completion of the study, using the 10 point Iowa Pain scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sexual function between visit 1 and visit 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Change in sexual function based on the female sexual function index (19 questions, one final score, maximum score of 36) where the patients fill a questionnaire prior to the first treatment session and after the completion of the treatment at week 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Pelvic Rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trigger Point Injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trigger point injections will be administered on weekly basis for a total of 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride</intervention_name>
    <description>The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.</description>
    <arm_group_label>Trigger Point Injections</arm_group_label>
    <other_name>Triamcinolone Acetonide-Total dose of 40mg, Volume 2 ml</other_name>
    <other_name>Bupivacaine Hydrochloride-Strength 0.5%, Volume 18ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pelvic Rehabilitation</intervention_name>
    <description>Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy</description>
    <arm_group_label>Pelvic Rehabilitation</arm_group_label>
    <other_name>Pelvic floor massage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pelvic pain

          -  pelvic floor myalgia

          -  dyspareunia

          -  female

          -  age &gt; 18 years

        Exclusion Criteria:

          -  interstitial cystitis

          -  vaginal lesions / ulcerations

          -  prior trigger point injections in the past 6 months

          -  prior pelvic rehabilitation in the past 6 months

          -  laparoscopically documented endometriosis / pelvic adhesions or adhesive disease

          -  documented pelvic inflammatory disease identified within the past 6 months

          -  documented sexually transmitted disease within the past 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary South, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dani Zoorob, MD</last_name>
    <phone>5135629080</phone>
    <email>zoorobdg@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary South, MD</last_name>
    <phone>5135629080</phone>
    <email>southmm@ucmai.uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Urogynecology, University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dani Zoorob, MD</last_name>
      <phone>513-562-9080</phone>
      <email>zoorobdg@ucmail.uc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996 Mar;87(3):321-7.</citation>
    <PMID>8598948</PMID>
  </reference>
  <results_reference>
    <citation>Rao SS, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009 May 1;29(9):985-91. doi: 10.1111/j.1365-2036.2009.03964.x. Epub 2009 Feb 13.</citation>
    <PMID>19222415</PMID>
  </results_reference>
  <results_reference>
    <citation>Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26(1):59-62.</citation>
    <PMID>17195176</PMID>
  </results_reference>
  <results_reference>
    <citation>Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):46-50.</citation>
    <PMID>15089868</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Mary South</investigator_full_name>
    <investigator_title>MD, Director of Female Pelvic Medicine &amp; Reconstructive Surgery</investigator_title>
  </responsible_party>
  <keyword>Pelvic Floor Myalgia</keyword>
  <keyword>Trigger Point Injections</keyword>
  <keyword>Pelvic Rehabilitation</keyword>
  <keyword>Dyspareunia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspareunia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 31, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 27, 2014</submitted>
    <returned>September 5, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

